Securities code: 688488 securities abbreviation: Jiangsu Aidea Pharmaceutical Co.Ltd(688488) Announcement No.: 2022-015 Jiangsu Aidea Pharmaceutical Co.Ltd(688488)
Announcement on the results of share reduction by shareholders through centralized bidding
The board of directors, all directors and relevant shareholders of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law. Important content tips:
Basic information of shareholders’ shareholding
Before the implementation of the reduction plan, the shareholder Jiangsu Yida M & a growth equity investment fund (limited partnership) (hereinafter referred to as “M & a growth”) held 14561640 shares of Jiangsu Aidea Pharmaceutical Co.Ltd(688488) (hereinafter referred to as “the company”), accounting for 3.47% of the total share capital of the company; Jiangsu high investment Xinhai Venture Capital Co., Ltd. (hereinafter referred to as “high investment Xinhai”) holds 12134880 shares of the company, accounting for 2.89% of the total share capital of the company; Jiangsu talent innovation venture capital partnership (limited partnership) (hereinafter referred to as “talent fund”) holds 3640320 shares of the company, accounting for 0.87% of the total share capital of the company. M & a growth, high-tech investment Xinhai and talent fund jointly hold 30336840 shares of the company, accounting for 7.22% of the total share capital of the company. The shares of the above shareholders are from the shares held before the company’s initial public offering and listing, and the restrictions on sales have been lifted and put on the market on July 20, 2021. The fund managers of M & a growth, high investment Xinhai and talent fund are controlled by Jiangsu Yida Equity Investment Fund Management Co., Ltd., and the above shareholders constitute the relationship of persons acting in concert.
Implementation results of centralized bidding reduction plan
On July 21, 2021, the company opened the website of Shanghai Stock Exchange (www.sse. Com. CN.) Disclosed the announcement of Jiangsu Aidea Pharmaceutical Co.Ltd(688488) shareholders’ share reduction plan through centralized bidding (Announcement No.: 2021-034): M & a growth, high investment Xinhai and talent fund plan to reduce the shares of the company through centralized bidding, with a total of no more than 6% (i.e. 25200000 shares) of the total shares of the company. The reduction period is within six months after 15 trading days from the date of announcement of the reduction plan, And the total number of shares reduced through centralized bidding trading of the stock exchange within any continuous 30 days shall not exceed 1% of the total number of shares of the company.
On February 6, 2022, the company received the notice of completion of share reduction plan jointly issued by the above shareholders
Letter. As of the issuance date of the notification letter, the implementation period of this reduction plan has expired. During the implementation of the reduction plan, the above shareholders reduced 9147105 shares through centralized bidding transactions, accounting for 2.1779% of the total share capital of the company, of which 2185735 shares were reduced by M & a growth, accounting for 0.5204% of the total share capital of the company, 6599270 shares were reduced by high-tech investment Xinhai, accounting for 1.5713% of the total share capital of the company, and 362100 shares were reduced by talent fund, Accounting for 0.0862% of the total share capital of the company.
1、 Basic information of the subject of centralized bidding reduction before reduction
Shareholder name shareholder identity shareholding quantity shareholding proportion current shareholding source (share)
M & a growth, more than 5% obtained before non first IPO:
High tech investment Xinhai, major shareholder 30336840 7.22% 30336840 shares
Talent fund
There are persons acting in concert with the above reduction subjects:
Name of shareholders, number of shares held, proportion of shares held, concerted action relationship, original (share) cause
7.22% of M & a growth, high investment Xinhai and talent fund management M & a growth and high investment Xin 30336840 are controlled by Jiangsu Yida equity group 1 Haihai and talent fund investment fund management Co., Ltd, Controlled by the same actual controller.
Total 30336840 7.22% –
2、 Implementation results of the centralized bidding reduction plan (I) major shareholders and directors, supervisors and senior executives disclose the implementation results of the centralized bidding reduction plan due to the following matters: the disclosed reduction time interval expires
Name of shareholder number of holdings reduction proportion of holdings reduction during the period of holdings reduction method of holdings reduction price range total amount of holdings reduction completion status of holdings current number of shares (shares) (yuan / share) (yuan) status proportion of shares (shares)
M & a growth, August 11, 2021 ~ centralized bidding not completed:
High tech investment Xinhai, 9147105 2.18% 2022 / 1 / 21 transaction 16.07-19.43 154128369 16052895 shares 21189735 5 5.05% talent fund
(II) whether the actual reduction is consistent with the previously disclosed reduction plan and commitment √ yes □ no (III) whether the reduction period expires and whether the reduction has not been implemented □ not implemented √ implemented
(IV) whether the actual reduction has not reached the minimum reduction quantity (proportion) of the reduction plan □ not reached √ reached (V) whether the reduction plan is terminated in advance □ yes √ no
It is hereby announced.
Jiangsu Aidea Pharmaceutical Co.Ltd(688488) board of directors February 8, 2022
